Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mannan-conjugated allergoid (polymerized) dermatophagoides pteronyssinus + dermatophagoides farinae
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
Mannan-conjugated allergoid (polymerized) Dermatophagoides pteronyssinus + Dermatophagoides farinae is a next-generation allergen immunotherapy (AIT) vaccine developed by Inmunotek. It consists of polymerized allergoids derived from the house dust mites *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, which are chemically modified with glutaraldehyde to reduce IgE-mediated allergenicity while preserving immunogenicity. These allergoids are covalently conjugated to mannan, a yeast-derived polysaccharide that acts as a biological adjuvant by targeting the mannose receptor (CD206) on dendritic cells. This targeted delivery enhances allergen uptake and promotes a shift in the immune response from a pro-allergic Th2 profile toward a tolerant Th1 and regulatory T-cell (Treg) profile. The drug is administered parenterally and is intended to provide long-term relief for patients with allergic respiratory diseases.
- Other names
- mannan-conjugated allergoid (polymerized) Dermatophagoides pteronyssinus + Dermatophagoides farinaemannan-conjugated house dust mite allergoid immunotherapymannan-conjugated house dust mite allergoidmannan-conjugated polymerized allergoids from Dermatophagoides pteronyssinus and Dermatophagoides farinae
02
Targets
CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)
Beyond the preview
Go deeper on mannan-conjugated allergoid (polymerized) dermatophagoides pteronyssinus + dermatophagoides farinae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mannan-conjugated allergoid (polymerized) dermatophagoides pteronyssinus + dermatophagoides farinae.